Funding for this research was provided by:
Massachusetts Lions Club
Research to Prevent Blindness
The Capes Foundation (process no 88887.369769/2019-00)
Foundation for the National Institutes of Health (R01EY015130, R01EY017011, R01EY011289)
Foundation for the National Institutes of Health (EY014800)
Champalimaud Vision Award
Beckman-Argyros Award in Vision Science
Retina Research Foundation
Yale School of Medicine
Received: 19 June 2020
Accepted: 11 August 2020
First Online: 20 August 2020
Ethics approval and consent to participate
: This study was approved by the Institutional Review Board for Tufts Medical Center, and patient consent was waived to analyze retrospective data.
: Not applicable.
: AEM: Novartis, Optos, Optovue, Eschenbach (personal fees). MQEM: Novartis, Bayer, Allergan (personal fees). JGF: Topcon (grants); Optovue, Carl Zeiss Meditech (patents); Optovue (consultant, personal financial interest). CRB: Carl Zeiss Meditec, Optovue, Genentech, Allergan (speaker fees). JSD: Carl Zeiss Meditec, Optovue (funding), Aldeyra, Allergan, Aura Biosciences, Bausch Health, Beyeonics, Merck, Novartis, Roche (Consulting); Eleven Oncology, Eye-Point Pharma (Director of Entity); Hemera Biosciences (stock/options). NKW: Nidek, Topcon (Speaker fees); Topcon, Roche/Genentech, Regeneron, Apellis, Astellas, Boehringer Ingelheim, Novartis (Consulting); Roche Genentech, Astellas, Boehringer Ingelheim, Novartis, Carl Zeiss Meditech, Topcon, Carl Zeiss Meditec (Advisory role); Gyroscope (Officer of entity). ESL, ECG, LSMM, SG, IND, AYA, EM, NM, UC, AW, MEH: No disclosures.